Pfizer chooses LBIC: Apex for New Internal Medicine Innovation Center (IMIC)

LBIC: Apex ‎ |‎ ‎ Tribeca, London

31 Jul 2026

Pfizer has announced the opening of its new Internal Medicine Innovation Center (IMIC) at LBIC: Apex, further strengthening our growing community of world-class life science innovators in the heart of London’s King's Cross Knowledge Quarter.

The centre builds on Pfizer’s acquisition of Metsera, bringing together UK scientists from this group with existing Pfizer researchers in one new location. The IMIC will focus on the discovery and development of peptide-based therapeutics, contributing to Pfizer’s global pipeline of potential treatments for conditions such as obesity and cardiometabolic disease.

The site will be home to highly skilled scientists who have industry-leading expertise in peptide-based drug discovery and have contributed to the development of obesity medicines in Pfizer’s current pipeline.

Amanda Keightley-Pugh, Chief Commercial Officer at LBIC, commented:

"We are delighted to welcome Pfizer's new Internal Medicine Innovation Center to LBIC: Apex. This investment is a strong endorsement of the UK's life sciences ecosystem and the collaborative environment we have built here within the Knowledge Quarter. By bringing together exceptional scientific talent and strengthening links with leading academic institutions, Pfizer's presence at LBIC will help foster innovation that has the potential to improve the lives of patients around the world. We look forward to supporting the team as they become part of our vibrant community."

Pfizer joins a strong community of life science innovators benefiting from LBIC's specialist facilities, biological services and scientific expertise across human and animal health.

Photo: Photographs by Photographer London